

Pharmacological Modulation of Inflammatory Pathways: Emerging Therapeutic Targets

Kirti C. Godse^{1*}, Pawar Shravani Prakash¹, Phanse Milind Dilip¹, Sujit Vitthal Abhang¹, Swapnil Mohan Shipate¹

¹Arvind Gavali College of Pharmacy, Jaitapur, Satara-415004, Maharashtra, India

*Corresponding Author E-mail: kirti.godse1994@gmail.com

Abstract:

Inflammation is a complex biological response crucial for host defence, but when dysregulated, it contributes to chronic diseases such as autoimmune disorders, metabolic syndromes, and cancer. Recent advances in pharmacology have identified novel therapeutic targets within inflammatory pathways, including inflammasomes, cytokine signalling, and epigenetic regulation. This review discusses the latest developments in pharmacological modulation of inflammatory responses, focusing on selective inflammasome inhibitors, cytokine-targeted biologics, and small molecules with anti-inflammatory properties. These emerging therapies hold promise for treating refractory inflammatory diseases with improved efficacy and safety profiles.

Keywords: Inflammatory Pathways; Pharmacological; Cytokine; chronic diseases

Received: Jan. 14, 2026

Revised: Feb. 18, 2026

Accepted: March. 15, 2026

Published: April 10, 2025

DOI: <https://doi.org/10.64474/3107-6726.Vol2.Issue1.3>

<https://jepmr.nknpub.com/1/issue/archive>

This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

1. Introduction

Inflammation is a complex and highly regulated physiological defense mechanism designed to protect the body from infections, injuries, and harmful stimuli. It involves the precise coordination of immune cells and molecular signaling pathways that trigger the release of pro-inflammatory cytokines such as interleukin-1 β (IL-1 β), interleukin-6 (IL-6), and tumor necrosis factor (TNF) ¹. These cytokines play a crucial role in amplifying immune responses and recruiting additional immune cells to the site of injury or infection. However, when inflammation becomes chronic or dysregulated, it contributes to the progression of several

pathological conditions, including autoimmune disorders, cardiovascular diseases, and cancer 2-3.

Traditionally, inflammation has been managed through the use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs). While these treatments are effective in reducing symptoms, their prolonged use is often associated with severe side effects such as gastrointestinal ulcers, cardiovascular complications, and immunosuppression. This limitation has driven researchers to focus on more specific, molecularly targeted therapies that can modulate inflammation at its roots without disrupting normal immune functions 4-5.

A major breakthrough in understanding inflammatory control mechanisms came with the discovery of inflammasomes—cytosolic multiprotein complexes that detect pathogenic microorganisms and cellular stress signals. Once activated, inflammasomes initiate the maturation and release of potent pro-inflammatory cytokines like IL-1 β and IL-18, which play key roles in innate immunity 6. The dysregulation of these complexes, however, is strongly linked to chronic inflammatory and metabolic disorders, making them attractive therapeutic targets for drug development.

In recent years, attention has also shifted toward the role of epigenetic mechanisms in regulating inflammation. Modifications such as DNA methylation, histone acetylation, and microRNA expression have been shown to control the transcription of inflammatory genes, suggesting that epigenetic modulators could serve as novel anti-inflammatory agents 7. Together, the expanding understanding of inflammatory diseases and epigenetic regulation has transformed the therapeutic outlook for inflammatory diseases, paving the way for precision medicine approaches that offer improved efficacy with fewer adverse effects. (Figure 1)




Figure 1: Overview of inflammasome complex activation and downstream signaling.

2. Inflammasomes as Therapeutic Targets

Inflammasomes are specialized cytosolic multiprotein complexes that act as innate immune sensors, playing a central role in detecting microbial infections, cellular stress, and metabolic disturbances. Upon activation, these complexes trigger the activation of caspase-1, which in turn processes pro-inflammatory cytokines such as interleukin-1 β (IL-1 β) and interleukin-18 (IL-18) into their active forms ⁸. (Figure 2) This cascade also initiates pyroptosis, a form of programmed cell death that helps eliminate infected or damaged cells. However, excessive or uncontrolled inflammasome activation has been closely linked to the pathogenesis of numerous inflammatory and autoimmune diseases, including gout, type 2 diabetes, Alzheimer’s disease, and rheumatoid arthritis ⁹.

IL-1 signaling pathway and pharmacological blockade by cytokine-targeted biologics




Figure 2: IL-1 signaling pathway and pharmacological blockade by cytokine-targeted biologics

Several inflammasome subtypes have been identified, including NLRP3, NLRP1, NLRC4, AIM2, and Pypin, each recognizing distinct danger signals¹⁰. Among these, the NLRP3 inflammasome is the most extensively studied due to its broad range of activating stimuli, such as potassium efflux, mitochondrial dysfunction, reactive oxygen species, and microbial components¹². Because of its pivotal role in mediating chronic inflammation, the NLRP3 inflammasome has become a prime therapeutic target in drug discovery efforts aimed at controlling inflammatory responses at their source¹¹.

Pharmacological Inhibition of NLRP3 offers a promising strategy for preventing the excessive release of IL-1 β and IL-18 without completely shutting down the body's normal immune defenses. One of the most potent and selective inhibitors developed so far is MCC950 (also known as CRID3), which binds to the NACHT domain of NLRP3, blocking ATP hydrolysis required for its activation¹³. This compound has demonstrated significant efficacy in preclinical models of diseases such as atherosclerosis, gout, inflammatory bowel disease, and neurodegeneration. Another agent, Tranilast, suppresses NLRP3 activation by targeting the same NACHT domain and by inhibiting NF- κ B signaling pathways, showing encouraging results in models of arthritis¹⁴. Similarly, OLT1177 is a small-molecule inhibitor in clinical development that effectively blocks IL-1 β release mediated by NLRP3 and is being evaluated for therapeutic use in acute gout and other inflammatory disorders.

In addition to synthetic molecules, several natural compounds have shown potential in regulating inflammasome activity. For example, Oridonin, a bioactive diterpenoid, disrupts the interaction between NLRP3 and NEK7 while simultaneously inhibiting NF- κ B and MAPK signaling pathways¹⁵⁻¹⁶. These dual effects make natural products valuable scaffolds for designing safer anti-inflammatory drugs. By targeting inflammasomes upstream—before cytokine release occurs, these therapeutic approaches provide a more comprehensive means of controlling inflammation compared to simply blocking downstream cytokine activity. This upstream intervention not only helps mitigate chronic inflammatory damage but also reduces the risk of systemic immune suppression, offering a more balanced and effective therapeutic strategy for inflammatory diseases¹⁷⁻¹⁸.

3. Cytokine-Targeted Biologics

Cytokines are key signaling molecules in the inflammatory cascade, orchestrating immune cell activation and communication during both acute and chronic inflammation. Among them, interleukin-1 β (IL-1 β) stands out as one of the most potent pro-inflammatory cytokines, driving a range of autoinflammatory and chronic inflammatory diseases¹⁹⁻²⁰. Dysregulated IL-1 β signaling has been implicated in conditions such as rheumatoid arthritis, gout, systemic juvenile idiopathic arthritis, and Cryopyrin-Associated Periodic Syndromes (CAPS). Consequently, therapeutic strategies designed to block IL-1 β activity have gained immense attention, leading to the development of several biologics that specifically target this cytokine or its receptor²¹.

One of the first biologic agents developed for IL-1 blockade was Anakinra, a recombinant form of the naturally occurring interleukin-1 receptor antagonist (IL-1Ra). By competitively binding to the IL-1 receptor, Anakinra prevents IL-1 β from initiating downstream inflammatory signaling. It has shown significant clinical efficacy in rheumatoid arthritis and CAPS²²⁻²³. However, due to its relatively short half-life, Anakinra requires daily subcutaneous administration, which can affect patient compliance in long-term treatment scenarios.

In contrast, Canakinumab is a fully human monoclonal antibody that directly neutralizes IL-1 β with high specificity. Its extended half-life allows for monthly dosing, offering a more convenient treatment option. Beyond its success in managing autoinflammatory diseases, Canakinumab has also demonstrated promising cardiovascular and oncological benefits, highlighting its potential to modulate inflammation-associated comorbidities²⁴⁻²⁵.

Another notable biologic is Riloncept, a fusion protein designed as a soluble decoy receptor. It combines key domains of the IL-1 receptor (IL-1R1) and the IL-1 receptor accessory protein (IL-1RAcP), enabling it to sequester IL-1 β and prevent receptor-mediated signaling. Riloncept has proven particularly effective in the treatment of CAPS and Schnitzler's syndrome, conditions characterized by excessive IL-1 activity²⁶⁻²⁷.

Despite their clinical success, cytokine-targeted biologics are not without limitations. Frequent dosing regimens for some agents, high production costs, and the increased risk of opportunistic infections due to immune suppression remain significant challenges. Moreover, these therapies often require parenteral administration, which can further limit accessibility and patient adherence.

Nevertheless, the advent of IL-1 β -targeted biologics represents a major leap forward in the management of autoinflammatory and chronic inflammatory disorders²⁸. Ongoing research continues to focus on developing next-generation biologics and small-molecule inhibitors with improved pharmacokinetics, lower immunogenicity, and broader accessibility—paving the way toward safer and more efficient cytokine-targeted therapies²⁹.

4. Epigenetic Modulation in Inflammation

Epigenetic regulation serves as a critical control layer in the orchestration of inflammatory responses, determining how immune-related genes are expressed without altering the underlying DNA sequence³⁰. These mechanisms—primarily DNA methylation, histone modifications (such as acetylation and methylation), and non-coding RNA expression—act as molecular switches that can either silence or activate genes involved in inflammation. Through these modifications, the body maintains a delicate balance between immune activation and resolution, ensuring that inflammatory responses are timely and proportionate. However, persistent disruptions in epigenetic regulation can lead to chronic inflammation, autoimmune diseases, and even cancer³¹.

Pharmacological modulation of epigenetic pathways has emerged as a cutting-edge therapeutic strategy to precisely fine-tune inflammatory signaling. Unlike traditional anti-inflammatory drugs that target specific cytokines or enzymes, epigenetic modulators can reprogram the expression of entire gene networks, offering a more systemic and durable approach to controlling inflammation³².

One promising example is ACT001, a derivative of micheliolide, which exhibits potent anti-inflammatory activity by inhibiting the IL-6/STAT3 signaling axis. This compound has demonstrated significant efficacy in preclinical models of sepsis and systemic inflammation, where overactivation of inflammatory pathways leads to severe tissue damage³³⁻³⁴. By modulating gene transcription rather than blocking a single protein target, ACT001 provides a broader yet controlled suppression of inflammation.

Another notable agent is Bergamottin, a naturally occurring compound known for its sirtuin-activating properties. Sirtuins are a family of histone deacetylases that regulate cellular metabolism and stress responses³⁵. By activating sirtuins, Bergamottin suppresses NF-κB signaling, one of the central pathways driving inflammation, and reduces the production of key inflammatory mediators. Its potential therapeutic value has been observed in osteoarthritis models, where chronic low-grade inflammation contributes to joint degeneration³⁶.

Beyond small molecules, advances in non-coding RNA-based therapeutics, such as microRNA mimics or inhibitors, are also showing promise in restoring epigenetic balance. These molecules can modulate the expression of multiple inflammatory genes simultaneously, providing another dimension to personalized inflammation control³⁷.

Altogether, epigenetic therapeutics represent an exciting and rapidly expanding frontier in the management of chronic inflammatory diseases. By complementing conventional therapies that target cytokines or inflammasomes, these agents offer the potential for longer-lasting benefits with fewer side effects. The integration of epigenetic modulation into clinical practice could redefine how inflammation is treated—shifting the focus from symptom suppression to the reprogramming of inflammatory gene expression at its very source³⁸⁻³⁹.

5. Future Therapeutic Directions

The field of inflammation research is rapidly evolving, with a growing focus on selective inflammasome-targeted therapies that offer precise and safer control over immune responses. Current clinical trials evaluating NLRP3 inhibitors such as *IZD334* and *Inzomelid* mark a major milestone in this direction⁴⁰. These next-generation compounds are designed to achieve high selectivity, oral bioavailability, and improved safety profiles, addressing many of the limitations associated with traditional biologics and systemic anti-inflammatory drugs. By directly modulating inflammasome activation, such inhibitors have the potential to suppress chronic inflammation without compromising essential immune defenses⁴¹⁻⁴².

The future of inflammation management lies in combination therapy, integrating multiple therapeutic modalities that target distinct yet interconnected pathways. A synergistic approach—combining biologics (for cytokine neutralization), inflammasome inhibitors (for upstream control of immune activation), and epigenetic modulators (for transcriptional regulation of inflammatory genes)—could provide a more comprehensive and long-lasting solution to chronic inflammatory conditions⁴³⁻⁴⁴. This multi-target strategy not only enhances therapeutic efficacy but also minimizes the need for high-dose monotherapy, thereby reducing the risk of systemic toxicity and immune suppression.

Moving forward, precision drug design will play a pivotal role in developing safer, patient-specific anti-inflammatory agents. Advances in structural biology, computational modeling, and AI-driven drug discovery are enabling researchers to identify and optimize small molecules that interact with key regulatory proteins at the molecular level⁴⁵⁻⁴⁶. Moreover, the development of oral formulations for inflammasome inhibitors and biologic mimetics will further improve patient compliance and accessibility.

However, as these innovative therapeutics progress toward clinical translation, long-term safety profiling remains a crucial requirement. Chronic inflammatory diseases often require prolonged treatment, and understanding the cumulative effects of inflammasome inhibition, cytokine modulation, and epigenetic reprogramming will be essential to avoid unintended immune dysregulation⁴⁷⁻⁴⁸.

Ultimately, the integration of molecularly targeted drugs, advanced biologics, and epigenetic therapies heralds a new era of personalized anti-inflammatory medicine. With continued research emphasizing multi-modal interventions, improved pharmacokinetics, and robust safety monitoring, the next generation of inflammation therapeutics is poised to deliver more effective, durable, and safer treatment outcomes for patients worldwide⁴⁹⁻⁵⁰.

6. Conclusion

Inflammation therapy is undergoing a paradigm shift—from conventional, broad-spectrum immunosuppressants toward precise molecular interventions that target specific signaling and regulatory nodes within the immune network. By focusing on inflammasomes, cytokine pathways, and epigenetic regulators, researchers are developing an integrated framework capable of addressing both acute and chronic inflammatory disorders at their roots.

This evolution reflects a deeper understanding of immune regulation and a commitment to minimizing collateral damage often seen with traditional therapies. The combination of inflammasome inhibitors, cytokine-targeted biologics, and epigenetic modulators represents a holistic therapeutic strategy that balances efficacy with safety.

As next-generation small molecules with oral bioavailability and multi-target capabilities continue to emerge, the landscape of anti-inflammatory drug discovery is being redefined. These advancements promise not only to improve treatment outcomes but also to reduce the

global burden of inflammation-associated diseases, ushering in an era of precision, personalization, and prevention in pharmacological management of inflammation.

Reference:

1. Andrabi, S. M., Sharma, N. S., Karan, A., Shahriar, S. M. S., Cordon, B., Ma, B., & Xie, J. (2023). Nitric oxide: Physiological functions, delivery, and biomedical applications. *Advanced Science*, *10*, e2303259.
2. Chatterjee, A., Black, S. M., & Catravas, J. D. (2008). Endothelial nitric oxide (NO) and its pathophysiologic regulation. *Vascular Pharmacology*, *49*, 134–140.
3. Cyr, A. R., Huckaby, L. V., Shiva, S. S., & Zuckerbraun, B. S. (2020). Nitric oxide and endothelial dysfunction. *Critical Care Clinics*, *36*, 307–321.
4. Roy, R., Wilcox, J., Webb, A. J., & O’Gallagher, K. (2023). Dysfunctional and dysregulated nitric oxide synthases in cardiovascular disease: Mechanisms and therapeutic potential. *International Journal of Molecular Sciences*, *24*, 15200.
5. Tran, N., Garcia, T., Aniq, M., Ali, S., Ally, A., & Nauli, S. M. (2022). Endothelial nitric oxide synthase (eNOS) and the cardiovascular system: In physiology and in disease states. *American Journal of Biomedical Science and Research*, *15*, 153–177.
6. Krol, M., & Kepinska, M. (2020). Human nitric oxide synthase—Its functions, polymorphisms, and inhibitors in the context of inflammation, diabetes, and cardiovascular diseases. *International Journal of Molecular Sciences*, *22*, 10056.
7. Forstermann, U., & Sessa, W. C. (2012). Nitric oxide synthases: Regulation and function. *European Heart Journal*, *33*, 829–837.
8. Scioli, M. G., Storti, G., D’Amico, F., Rodriguez Guzman, R., Centofanti, F., Doldo, E., Cespedes Miranda, E. M., & Orlandi, A. (2020). Oxidative stress and new pathogenetic mechanisms in endothelial dysfunction: Potential diagnostic biomarkers and therapeutic targets. *Journal of Clinical Medicine*, *9*, 1995.
9. Iova, O. M., Marin, G. E., Lazar, I., Stanescu, I., Dogaru, G., Nicula, C. A., & Bulboaca, A. E. (2023). Nitric oxide/nitric oxide synthase system in the pathogenesis of neurodegenerative disorders—An overview. *Antioxidants*, *12*, 753.
10. Huang, J. B., Chen, Z. R., Yang, S. L., & Hong, F. F. (2023). Nitric oxide synthases in rheumatoid arthritis. *Molecules*, *28*, 4414.
11. Deeb, R. S., & Hajjar, D. P. (2016). Repair mechanisms in oxidant-driven chronic inflammatory disease. *American Journal of Pathology*, *186*, 1736–1749.
12. Soufli, I., Toumi, R., Rafa, H., & Touil-Boukoffa, C. (2016). Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases. *World Journal of Gastrointestinal Pharmacology and Therapeutics*, *7*, 353–360.
13. Guo, Q., Jin, Y., Chen, X., Ye, X., Shen, X., Lin, M., Zeng, C., Zhou, T., & Zhang, J. (2024). NF-kappaB in biology and targeted therapy: New insights and translational implications. *Signal Transduction and Targeted Therapy*, *9*, 53.

14. Zhang, W., Lin, H., Zou, M., Yuan, Q., Huang, Z., Pan, X., & Zhang, W. (2022). Nicotine in inflammatory diseases: Anti-inflammatory and pro-inflammatory effects. *Frontiers in Immunology*, *13*, 826889.
15. Ahmed, S. M., Luo, L., Namani, A., Wang, X. J., & Tang, X. (2017). Nrf2 signaling pathway: Pivotal roles in inflammation. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, *1863*, 585–597.
16. Eichwald, T., da Silva, L. B., Staats Pires, A. C., Niero, L., Schnorrenberger, E., Filho, C. C., Espindola, G., Huang, W. L., Guillemin, G. J., & Abdenur, J. E. (2023). Tetrahydrobiopterin: Beyond its traditional role as a cofactor. *Antioxidants*, *12*, 1037.
17. Nakazawa, H., Chang, K., Shinozaki, S., Yasukawa, T., Ishimaru, K., Yasuhara, S., Yu, Y. M., Martyn, J. A., Tompkins, R. G., & Shimokado, K. (2017). iNOS as a driver of inflammation and apoptosis in mouse skeletal muscle after burn injury. *PLoS ONE*, *12*, e0170391.
18. Janaszak-Jasiecka, A., Ploska, A., Wieronska, J. M., Dobrucki, L. W., & Kalinowski, L. (2023). Endothelial dysfunction due to eNOS uncoupling: Molecular mechanisms as potential therapeutic targets. *Cellular and Molecular Biology Letters*, *28*, 21.
19. Edgar, K. S., Galvin, O. M., Collins, A., Katusic, Z. S., & McDonald, D. M. (2017). BH4-mediated enhancement of endothelial nitric oxide synthase activity reduces hyperoxia-induced endothelial damage and preserves vascular integrity in the neonate. *Investigative Ophthalmology & Visual Science*, *58*, 230–241.
20. Bi, X. Y., He, X., Zhao, M., Yu, X. J., & Zang, W. J. (2013). Role of endothelial nitric oxide synthase and vagal activity in the endothelial protection of atorvastatin in ischemia/reperfusion injury. *Journal of Cardiovascular Pharmacology*, *61*, 391–400.
21. Salvagno, M., Sterchele, E. D., Zaccarelli, M., Mrakic-Sposta, S., Welsby, I. J., Balestra, C., & Taccone, F. S. (2024). Oxidative stress and cerebral vascular tone: The role of reactive oxygen and nitrogen species. *International Journal of Molecular Sciences*, *25*, 3007.
22. Zhu, L. J., Li, F., & Zhu, D. Y. (2023). nNOS and neurological, neuropsychiatric disorders: A 20-year story. *Neuroscience Bulletin*, *39*, 1439–1453.
23. Ziegler, K., Kunert, A. T., Reinmuth-Selzle, K., Leifke, A. L., Widera, D., Weller, M. G., Schuppan, D., Frohlich-Nowoisky, J., Lucas, K., & Poschl, U. (2020). Chemical modification of pro-inflammatory proteins by peroxynitrite increases activation of TLR4 and NF-kappaB. *Redox Biology*, *37*, 101581.
24. Pacher, P., Beckman, J. S., & Liaudet, L. (2007). Nitric oxide and peroxynitrite in health and disease. *Physiological Reviews*, *87*, 315–424.
25. Ramdial, K., Franco, M. C., & Estevez, A. G. (2017). Cellular mechanisms of peroxynitrite-induced neuronal death. *Brain Research Bulletin*, *133*, 4–11.
26. Griendling, K. K., Touyz, R. M., Zweier, J. L., Dikalov, S., Chilian, W., Chen, Y. R., Harrison, D. G., & Bhatnagar, A. (2016). Measurement of reactive oxygen species,

- reactive nitrogen species, and redox-dependent signaling in the cardiovascular system. *Circulation Research*, 119, e39–e75.
27. Perez-Torres, I., Manzano-Pech, L., Rubio-Ruiz, M. E., Soto, M. E., & Guarner-Lans, V. (2020). Nitrosative stress and its association with cardiometabolic disorders. *Molecules*, 25, 2555.
 28. Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023). Signaling pathways in rheumatoid arthritis: Implications for targeted therapy. *Signal Transduction and Targeted Therapy*, 8, 68.
 29. Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., & Jacobs, A. H. (2024). Neuroinflammation in Alzheimer disease. *Nature Reviews Immunology*.
 30. Liu, T., Zhang, L., Joo, D., & Sun, S. C. (2017). NF-kappaB signaling in inflammation. *Signal Transduction and Targeted Therapy*, 2, 17023.
 31. Jang, D. I., Lee, A. H., Shin, H. Y., Song, H. R., Park, J. H., Kang, T. B., Lee, S. R., & Yang, S. H. (2021). The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics. *International Journal of Molecular Sciences*, 22, 2719.
 32. Chen, S., Saeed, A., Liu, Q., Jiang, Q., Xu, H., Xiao, G. G., Rao, L., & Duo, Y. (2023). Macrophages in immunoregulation and therapeutics. *Signal Transduction and Targeted Therapy*, 8, 207.
 33. Ricciotti, E., & FitzGerald, G. A. (2011). Prostaglandins and inflammation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 31, 986–1000.
 34. Konya, V., Marsche, G., Schuligoi, R., & Heinemann, A. (2013). E-type prostanoid receptor 4 (EP4) in disease and therapy. *Pharmacology & Therapeutics*, 138, 485–502.
 35. Li, T., Liu, B., Mao, W., Gao, R., Wu, J., Deng, Y., Shen, Y., Liu, K., & Cao, J. (2019). Prostaglandin E(2) promotes nitric oxide synthase 2, platelet-activating factor receptor, and matrix metalloproteinase-2 expression in *Escherichia coli*-challenged ex vivo endometrial explants via the prostaglandin E(2) receptor 4/protein kinase A signaling pathway. *Thrombosis and Haemostasis*, 134, 65–73.
 36. Luo, M., He, N., Xu, Q., Wen, Z., Wang, Z., Zhao, J., & Liu, Y. (2024). Roles of prostaglandins in immunosuppression. *Clinical Immunology*, 265, 110298.
 37. Ermis, E., Nargis, T., Webster, K., Tersey, S. A., Anderson, R. M., & Mirmira, R. G. (2024). Leukotriene B4 receptor 2 governs macrophage migration during tissue inflammation. *Journal of Biological Chemistry*, 300, 105561.
 38. Filgueiras, L. R., Brandt, S. L., Wang, S., Wang, Z., Morris, D. L., Evans-Molina, C., Mirmira, R. G., Jancar, S., & Serezani, C. H. (2015). Leukotriene B4-mediated sterile inflammation promotes susceptibility to sepsis in a mouse model of type 1 diabetes. *Science Signaling*, 8, ra10.
 39. Miyabe, Y., Miyabe, C., & Luster, A. D. (2017). LTB4 and BLT1 in inflammatory arthritis. *Seminars in Immunology*, 33, 52–57.

40. Lavy, M., Gauttier, V., Poirier, N., Barille-Nion, S., & Blanquart, C. (2021). Specialized pro-resolving mediators mitigate cancer-related inflammation: Role of tumor-associated macrophages and therapeutic opportunities. *Frontiers in Immunology*, *12*, 702785.
41. Sun, T. W., Wu, Z. H., & Weng, X. S. (2015). Celecoxib can suppress expression of genes associated with PGE2 pathway in chondrocytes under inflammatory conditions. *International Journal of Clinical and Experimental Medicine*, *8*, 10902–10910.
42. Maghsoudi, H., Sheikhnia, F., Sitarek, P., Hajmalek, N., Hassani, S., Rashidi, V., Khodaghali, S., Mir, S. M., Malekinejad, F., & Kheradmand, F. (2023). The potential preventive and therapeutic roles of NSAIDs in prostate cancer. *Cancers*, *15*, 5435.
43. He, R., Chen, Y., & Cai, Q. (2020). The role of the LTB4–BLT1 axis in health and disease. *Pharmacological Research*, *158*, 104857.
44. Rolfes, M. C., Juhn, Y. J., Wi, C. I., & Sheen, Y. H. (2017). Asthma and the risk of rheumatoid arthritis: An insight into the heterogeneity and phenotypes of asthma. *Tuberculosis and Respiratory Diseases*, *80*, 113–135.
45. Hu, J., Huang, S., Liu, X., Zhang, Y., Wei, S., & Hu, X. (2022). miR-155: An important role in inflammation response. *Journal of Immunology Research*, *2022*, 7437281.
46. Pashangzadeh, S., Motallebnezhad, M., Vafashoar, F., Khalvandi, A., & Mojtavavi, N. (2021). Implications of the role of miR-155 in the pathogenesis of autoimmune diseases. *Frontiers in Immunology*, *12*, 669382.
47. Seddiki, N., Brezar, V., Ruffin, N., Levy, Y., & Swaminathan, S. (2014). Role of miR-155 in the regulation of lymphocyte immune function and disease. *Immunology*, *142*, 32–38.
48. Lv, F., Huang, Y., Lv, W., Yang, L., Li, F., Fan, J., & Sun, J. (2017). MicroRNA-146a ameliorates inflammation via TRAF6/NF-kappaB pathway in intervertebral disc cells. *Medical Science Monitor*, *23*, 659–664.
49. Artimovic, P., Spakova, I., Macejkova, E., Pribulova, T., Rabajdova, M., Marekova, M., & Zavacka, M. (2024). The ability of microRNAs to regulate the immune response in ischemia/reperfusion inflammatory pathways. *Genes and Immunity*, *25*, 277–296.
50. Liao, Z., Zheng, R., & Shao, G. (2023). Mechanisms and application strategies of miRNA-146a regulating inflammation and fibrosis at molecular and cellular levels. *International Journal of Molecular Medicine*, *51*, 1–16.